Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium ... - PubMed
We assessed the effects of the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on serum potassium levels in a pooled analysis of clinical trials in patients with type 2 diabetes mellitus (T2DM).
Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin …
No significant association was found between potassium-sparing medications (p > 0.05) and hyperkalemia, except for angiotensin receptor blockers (p = 0.017). The combination of dapagliflozin and furosemide significantly increased the risk of acute kidney injury (AKI) at the endpoint (p = 0.006).
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of …
Apr 8, 2022 · In each individual trial, the effects of SGLT2 inhibitors were assessed on time to first serum potassium ≥6.0 mmol/L and other potassium outcomes using the intention-to-treat population and included all central laboratory values after …
Mineral and Electrolyte Disorders With SGLT2i Therapy - PMC
Postulated effects of SGLT2is on serum electrolytes (sodium, potassium, and magnesium): inhibition of SGLT2 receptors promotes glycosuria, natriuresis, and osmotic diuresis, which in turn causes an elevation of aldosterone activity with increased kaliuresis and magnesuria.
The long-term effects of dapagliflozin in chronic kidney disease: a ...
Our analysis suggests that long-term treatment with dapagliflozin has the potential to substantively delay the time to adverse outcomes including kidney failure, which could have beneficial consequences for healthcare service delivery.
Effect Of Sglt2 Inhibitor Dapagliflozin On Sodium, Potassium …
The mean level of serum potassium was higher in the dapagliflozin group compared with the control group (p<0.001) on day 7/discharge. Mean serum sodium level was comparable and showed significant differences between the two groups following treatment (p-value=0.021).
Hot Topics: SGLT2 Inhibitors and Kidney Disease - The National …
Aug 12, 2024 · Lower serum potassium: Kidney patients can experience hyperkalemia or dangerously high blood potassium levels. SGLT2 inhibitors can help lower potassium, protecting the patient from serious heart problems.
Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium
Jan 12, 2016 · We assessed the effects of the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on serum potassium levels in a pooled analysis of clinical trials in patients with type 2 diabetes mellitus (T2DM).
Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in ...
Jan 13, 2016 · We assessed the effects of the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on serum potassium levels in a pooled analysis of clinical trials in patients with type 2 diabetes...
Conclusions: Use of SGLT2 inhibitors in T2DM reduced odds of inducing hyperkalaemia but had a minimal effect of lowering serum potassium. 1. Introduction. Sodium-glucose co-transporter 2 (SGLT2) inhibitors received EU approval for use for glycaemic control in …